Genomic profile of a secretory breast cancer with an ETV6–NTRK3 duplication

Background: Secretory breast cancer (SBC) is a rare entity characterised by indolent clinical behaviour, distinctive histological features and the presence of a recurrent chromosomal translocation t(12;15)(p13;q25), leading to the formation of the ETV6–NTRK3 fusion gene. Aim: To describe the molecular genetic features of a case of SBC which harbours a duplication of the t(12;15) translocation. Methods: Tiling path array comparative genomic hybridisation (aCGH) analysis and fluorescence in situ hybridisation (FISH) using in-house-generated probes for ETV6, NTRK3 and the fusion genes, centromeric probes for chromosomes 12 and 15, and a commercially available split-apart ETV6/NTRK3 probe. Results: FISH revealed the presence of a duplication of the translocation t(12;15), which resulted from the gain of one copy of the derivative chromosome der(15)t(12;15), retention of one normal copy of both ETV6 and NTRK3 genes and deletion of the derivative chromosome der(12)t(12;15). Consistent with FISH findings, aCGH revealed copy number gains of ETV6 and NTRK3 and deletions encompassing the regions centromeric to ETV6 and telomeric to NTRK3. Additional regions of copy number changes included gains of 10q21, 10q26.3, 12p13.3–p13.31 15q11–q25.3 and 16pq and losses of 6q24.1–q27, 12p13.2–q12 and 15q25.3–q26.3. Conclusions: To the best of our knowledge, this is the first time a carcinoma has been shown to harbour a duplication of the ETV6–NTRK3 translocation. The presence of an additional copy of the derivative chromosome der(15)t(12;15) coupled with deletion of the other derivative der(12)t(12;15) in the modal population of cancer cells suggests that this was either an early phenomenon or conferred additional growth advantage on neoplastic cells.

[1]  D. Berney,et al.  Duplication of the fusion of TMPRSS 2 to ERG sequences identifies fatal human prostate cancer , 2009 .

[2]  A. Ashworth,et al.  The genomic profile of HER2‐amplified breast cancers: the influence of ER status , 2008, The Journal of pathology.

[3]  M. Lambros,et al.  ESR1 amplification in endometrial carcinomas: hope or hyperbole? , 2008, The Journal of pathology.

[4]  A. Ashworth,et al.  Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast , 2008, The Journal of pathology.

[5]  A. Ashworth,et al.  Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas , 2008, The Journal of pathology.

[6]  Paul D. Levey,et al.  ESR1 gene amplification in breast cancer: a common phenomenon? , 2008, Nature Genetics.

[7]  Anne Vincent-Salomon,et al.  ESR1 gene amplification in breast cancer: a common phenomenon? , 2008, Nature Genetics.

[8]  I. Ellis,et al.  Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6‘split apart’ probes , 2008, Histopathology.

[9]  Alan Mackay,et al.  Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines , 2008, Laboratory Investigation.

[10]  J Cuzick,et al.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.

[11]  E. Resetkova,et al.  A Large, Fungating Breast Mass , 2009 .

[12]  O. Lingjaerde,et al.  ESR1 gene amplification in breast cancer: a common phenomenon? , 2008, Nature Genetics.

[13]  D. Birnbaum,et al.  Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer , 2007, Oncogene.

[14]  A. Ashworth,et al.  Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour , 2007, The Journal of pathology.

[15]  Alan Mackay,et al.  Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation , 2007, Laboratory Investigation.

[16]  S. Vieni,et al.  Secretory breast carcinoma with metastatic sentinel lymph node , 2006, World journal of surgical oncology.

[17]  Kenny Q. Ye,et al.  Novel patterns of genome rearrangement and their association with survival in breast cancer. , 2006, Genome research.

[18]  K Fenwick,et al.  Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse , 2006, The Journal of pathology.

[19]  E. Resetkova,et al.  A large, fungating breast mass. Secretory carcinoma with apocrine differentiation. , 2006, Archives of pathology & laboratory medicine.

[20]  A. Ashworth,et al.  Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization , 2006, Laboratory Investigation.

[21]  D. Amott,et al.  Secretory Carcinoma of the Breast , 2006, The breast journal.

[22]  A. Ashworth,et al.  Oncocytic change in pleomorphic adenoma: molecular evidence in support of an origin in neoplastic cells , 2006, Journal of Clinical Pathology.

[23]  Shridar Ganesan,et al.  X chromosomal abnormalities in basal-like human breast cancer. , 2006, Cancer cell.

[24]  P. Nederlof,et al.  A multiplex PCR predictor for aCGH success of FFPE samples , 2005, British Journal of Cancer.

[25]  A. Hagemeijer,et al.  Fusion of ETV 6 to MDS 1 / EVIJ as a Result of t ( 3 ; 12 ) ( q 26 ; p 13 ) in Myeloproliferative Disorders , 2006 .

[26]  J. Bourhis,et al.  Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia. , 2005, Cancer genetics and cytogenetics.

[27]  A. Aventín,et al.  Genetic abnormalities associated with the t(12;21) and their impact in the outcome of 56 patients with B-precursor acute lymphoblastic leukemia. , 2005, Cancer genetics and cytogenetics.

[28]  D. Birnbaum,et al.  ETV6 gene rearrangements in invasive breast carcinoma , 2005, Genes, chromosomes & cancer.

[29]  A. Ashworth,et al.  Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity , 2005, The Journal of pathology.

[30]  K. Tascilar,et al.  Secretory Carcinoma of the Breast , 2005, Oncology.

[31]  D. Gallardo-Rincón,et al.  Secretory carcinoma of the breast containing the ETV6-NTRK3 fusion gene in a male: case report and review of the literature , 2005, World journal of surgical oncology.

[32]  P. Sorensen,et al.  ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. , 2005, Seminars in cancer biology.

[33]  S. Chon,et al.  Secretory carcinoma of the breast diagnosed by fine needle aspiration. , 2005, Acta cytologica.

[34]  F. Aranda,et al.  Secretory carcinoma of the male breast: Correlation of aspiration cytology and pathology , 2005, Diagnostic cytopathology.

[35]  Kyung-Ja Cho,et al.  Breast mass in a 3-year-old girl: differentiation of secretory carcinoma versus abnormal thelarche by fine needle aspiration biopsy. , 2005, Surgery.

[36]  Jane Fridlyand,et al.  Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. , 2005, Human molecular genetics.

[37]  Emmanuel Barillot,et al.  Analysis of array CGH data: from signal ratio to gain and loss of DNA regions , 2004, Bioinform..

[38]  S. Bond,et al.  Secretory carcinoma in a 9‐year‐old girl , 2004, Diagnostic cytopathology.

[39]  Z. Szentirmay,et al.  Secretory breast cancer in a 7.5-year old boy. , 2004, Breast.

[40]  F. Pardal,et al.  Secretory breast carcinoma--case report and review of the medical literature. , 2004, Breast.

[41]  T. B. Culas,et al.  Secretory carcinoma of breast in a 17-year-old male , 2004, World journal of surgical oncology.

[42]  P. Sorensen,et al.  A fluorescence in situ hybridization study of ETV6‐NTRK3 fusion gene in secretory breast carcinoma , 2004, Genes, chromosomes & cancer.

[43]  A. Seki,et al.  Secretory Breast Carcinoma With Extensive Intraductal Component: Case Report , 2004, Ultrastructural pathology.

[44]  P. Sorensen,et al.  Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry. , 2003, Human pathology.

[45]  B. Moon,et al.  Secretory carcinoma of the breast , 2003, Journal of clinical ultrasound : JCU.

[46]  M. Hirokawa,et al.  Secretory Carcinoma of the Breast with a Cystically Dilated Intraductal Component: Report of a Case , 2003, Surgery Today.

[47]  M. Miyazaki,et al.  Phyllodes tumor arising in ectopic breast tissue of the axilla , 2003, Breast cancer.

[48]  C. Timmons,et al.  ETV6-NTRK3--Trk-ing the primary event in human secretory breast cancer. , 2002, Cancer cell.

[49]  P. Sorensen,et al.  Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. , 2002, Cancer cell.

[50]  T. Sano,et al.  Secretory carcinoma of the breast: a tumour analogous to salivary gland acinic cell carcinoma? , 2002, Histopathology.

[51]  M. Teixeira,et al.  Cytogenetic clues to breast carcinogenesis , 2002, Genes, chromosomes & cancer.

[52]  S. Shin,et al.  Invasive secretory (juvenile) carcinoma arising in ectopic breast tissue of the axilla. , 2001, Archives of pathology & laboratory medicine.

[53]  P. Sorensen,et al.  Absence of t(12;15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias. , 2001, Medical and pediatric oncology.

[54]  P. Jhabvala,et al.  Cytogenetic and Molecular Characterization of a Congenital Mesoblastic Nephroma , 2001, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[55]  M. Roussel,et al.  The MN1-TEL Fusion Protein, Encoded by the Translocation (12;22)(p13;q11) in Myeloid Leukemia, Is a Transcription Factor with Transforming Activity , 2000, Molecular and Cellular Biology.

[56]  H. Herz,et al.  Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: case report and review of the literature. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  J. F. Magee,et al.  Breast cancer in a 6-year-old child. , 2000, Journal of pediatric surgery.

[58]  A. Causse,et al.  At least five regions of imbalance on 6q in breast tumors, combining losses and gains , 2000, Genes, chromosomes & cancer.

[59]  K. Tanaka,et al.  Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). , 1999, Blood.

[60]  J. Goldman,et al.  Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12). , 1999, Blood.

[61]  J. Goldman,et al.  Fusion of ETV 6 to the Caudal-Related Homeobox Gene CDX 2 in Acute Myeloid Leukemia , 1999 .

[62]  F. Lemonnier,et al.  Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. , 1998, The Journal of clinical investigation.

[63]  M. Höglund,et al.  ETV6/ABL fusion is rare in Ph-negative chronic myeloid disorders , 1998, Leukemia.

[64]  P. Sorensen,et al.  A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma , 1998, Nature Genetics.

[65]  F. Lemonnier,et al.  Cytotoxic T Cell Response against the Chimeric ETV 6-AML 1 Protein in Childhood Acute Lymphoblastic Leukemia , 1998 .

[66]  D. Birnbaum,et al.  Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. , 1997, Cancer research.

[67]  P. Marynen,et al.  Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. , 1997, Blood.

[68]  P. Marynen,et al.  Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. , 1997, Cancer research.

[69]  C. Theillet,et al.  Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[70]  N. Takahashi,et al.  Duplication of chromosome 9 carrying a BCR/ABL chimeric gene in Philadelphia chromosome negative chronic myeloid leukemia. , 1996, Cancer genetics and cytogenetics.

[71]  C. Mathew,et al.  Loss of heterozygosity of the oestrogen receptor gene in breast cancer. , 1995, British Journal of Cancer.

[72]  R. Bruzzone,et al.  Karyotype evolution of Ph positive chronic myelogenous leukemia patients relapsed in advanced phases of the disease after allogeneic bone marrow transplantation. , 1991, Cancer genetics and cytogenetics.

[73]  M. Cranor,et al.  Secretory carcinoma of the breast. , 1991, Archives of pathology & laboratory medicine.

[74]  D. Jenkins,et al.  Secretory carcinoma of the breast in adults: emphasis on late recurrence and metastasis , 1989, Histopathology.

[75]  R. Zaino,et al.  Juvenile secretory carcinoma of the breast. , 1985, Journal of pediatric surgery.

[76]  F. Stewart,et al.  Breast carcinoma in children. , 1966, JAMA.

[77]  J. de Grouchy,et al.  [DUPLICATION OF A PH CHROMOSOME AND SUGGESTION OF CLONAL EVOLUTION IN CHRONIC MYELOCYTIC LEUKEMIA IN ACUTE TRANSFORMATION]. , 1965, Nouvelle revue francaise d'hematologie.